CD80-CD28 signaling controls the progression of inflammatory colorectal carcinogenesis

Oncotarget. 2015 Aug 21;6(24):20058-69. doi: 10.18632/oncotarget.2780.

Abstract

In patients with ulcerative colitis (UC) the cumulative risk of colon cancer is lower than the actual rate of dysplasia suggesting an efficient immune surveillance mechanism. Since the co-stimulatory molecule CD80 is overexpressed in dysplastic colonic mucosa of UC patients and T-cell activation entails effective costimulation, we aimed to evaluate the functional implication of CD80 signaling in colonic UC-associated carcinogenesis. In humans, we observed that the percentage of CD80+ and HLA-A+ IEC was increased in the dysplastic colonic mucosa of UC patients. In vitro, IEC activated CD8+ T-cells through a CD80-dependent pathway. Finally, in the AOM/DSS-induced colonic adenocarcinoma model CD80 signaling inhibition significantly increased the frequency and extension of high-grade dysplasia, whereas enhancing CD80 activity with an anti-CTLA4 antibody significantly decreased colonic dysplasia. In conclusion, CD80 signaling between IEC and T-cells represents a key factor controlling the progression from low to high grade dysplasia in inflammatory colonic carcinogenesis.

Keywords: CD8+ T cells; antigen presenting cells; colorectal carcinogenesis; intestinal epithelial cells; ulcerative colitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigen Presentation
  • B7-1 Antigen / immunology*
  • CD28 Antigens / immunology*
  • Colitis, Ulcerative / genetics
  • Colitis, Ulcerative / immunology*
  • Colitis, Ulcerative / pathology
  • Colonic Neoplasms / genetics
  • Colonic Neoplasms / immunology*
  • Colonic Neoplasms / pathology
  • Disease Progression
  • Humans
  • Lymphocyte Activation
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Signal Transduction
  • T-Lymphocytes / immunology

Substances

  • B7-1 Antigen
  • CD28 Antigens